Join our daily newsletter At The Bell to receive exclusive market insights
With more than seven million users on the HotCopper forums, every discussion and speculation can move Australian markets, which is why getting out in front of those trends is so important for any trader worth their salt.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
In this daily HotCopper Trends column, we break down the top three stocks talked about on any given trade day, and why they’ve drawn a daily focus.
Note: some listed companies may be clients.
- Resolution Minerals is out way in front when it comes to views of the company’s Monday announcement it’s found a new gold discovery on-site its Golden Gate South acreage; the company is still reporting it’s whittling its way to the NASDAQ.
- Paradigm Biopharmaceuticals meanwhile has announced it’s continuing a strategic pivot into the animal care sector with its osteoarthritis drug candidate now being tested on animals in oral form.
- Australian Mines Ltd meanwhile reported “exceptional” scandium grades at its Flemington asset, well received by the company’s investors with shares up 9% – to 1.8cps.
- New Age Exploration also landing on radars but for a trading halt; the nanocap is flagging upcoming “drilling results at the Wagyu Gold Project” – the vibe is that people are expecting they’l be good.
- Dreadnought Resources also reporting gold on Monday, this time reporting further high grade discoveries at its much-watched Mangaroon project.
- Finally, Memphasys has inked approval from Australian drug regulator TGA for its Felix tech which ultimately aims to enter the IVF market. Shares jumped 27% on the approval – but the company’s a nanocap at 0.7cps.
Join the discussion: See what’s trending right now on HotCopper, Australia’s largest stock forum, and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
